Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Pisculli

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Surgical Neurology International|March 10, 2016
Racemose neurocysticercosisKristin Krupa, Kelly Krupa, Mary L Pisculli, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|August 16, 2016
Odontogenic Sinusitis Resulting in Abscess Formation Within the Optic Chiasm and Tract: Case Report and ReviewGeorge M Ghobrial, Mary L Pisculli, James J Evans, et al.
Neurosurgery|February 28, 2008
Limitations of diffusion-weighted imaging in the diagnosis of postoperative infectionsChristopher J Farrell, Brian L Hoh, Mary L Pisculli, et al.
AIDS and Behavior|October 28, 2010
Factors associated with refusal of rapid HIV testing in an emergency departmentMary L Pisculli, William M Reichmann, Elena Losina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 28, 2012
Acceptability of fingerstick versus oral fluid rapid HIV testing: results from the universal screening for HIV infection in the emergency room (USHER Phase II) randomized controlled trialLaurel A Donnell-Fink, Christian Arbelaez, Jamie E Collins, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 18, 2026
Reduction in estimated glomerular filtration rate observed with doravirine is caused by inhibition of organic cation transporter 2Yang Li, Chitra Saran, Xiaoyan Chu, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2025
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Roger Paredes, Pedro Cahn, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Surgical Neurology International|March 10, 2016
Racemose neurocysticercosisKristin Krupa, Kelly Krupa, Mary L Pisculli, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|August 16, 2016
Odontogenic Sinusitis Resulting in Abscess Formation Within the Optic Chiasm and Tract: Case Report and ReviewGeorge M Ghobrial, Mary L Pisculli, James J Evans, et al.
Neurosurgery|February 28, 2008
Limitations of diffusion-weighted imaging in the diagnosis of postoperative infectionsChristopher J Farrell, Brian L Hoh, Mary L Pisculli, et al.
AIDS and Behavior|October 28, 2010
Factors associated with refusal of rapid HIV testing in an emergency departmentMary L Pisculli, William M Reichmann, Elena Losina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 28, 2012
Acceptability of fingerstick versus oral fluid rapid HIV testing: results from the universal screening for HIV infection in the emergency room (USHER Phase II) randomized controlled trialLaurel A Donnell-Fink, Christian Arbelaez, Jamie E Collins, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 18, 2026
Reduction in estimated glomerular filtration rate observed with doravirine is caused by inhibition of organic cation transporter 2Yang Li, Chitra Saran, Xiaoyan Chu, et al.
The Lancet. HIV|February 28, 2026
Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Sheetal Kassim, Roger Paredes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 13, 2025
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trialJürgen K Rockstroh, Roger Paredes, Pedro Cahn, et al.
Pageof 1